Biblioteca Virtuale per la Salute – Piemonte – "Le biblioteche non si fanno…crescono" A. Birrell

Sfoglia per AUTORE
PATRIARCA F
Collezione AOU Città della Salute di Torino

Items : 60

Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients. in European journal of haematology / Eur J Haematol. 2025 Jul;115(1):16-28. doi: 10.1111/ejh.14413. Epub 2025 Mar 19.

2025
AOU Città della Salute di Torino
AOU Novara

Quaresima M; Barbieri E; D'Arrigo G; Reddiconto G; Tripepi G; Morè S; Sica A; Mele G; Falcone AP; Mancuso K; Cangialosi C; Farina G; Vincelli ID; Paris L; Mina R; Fazio F; Bruzzese A; Vigna E; Della Pepa R; Mele A; Musso M; Palmieri S; Zamagni E; Conticello C; Bolli N; Pettine L; Petrucci MT; De Magistris C; Lotti F; et alii...

Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation. in Transplantation and cellular therapy / Transplant Cell Ther. 2025 Jan;31(1):26.e1-26.e13. doi: 10.1016/j.jtct.2024.10.015. Epub 2024 Nov 4.

2025
AOU Alessandria
AOU Città della Salute di Torino

Fanin R; Patriarca F; Selleri C; Tozzi M; Carnevale F; Boncompagni R; Antonioli E; Oldani E; Degrandi E; Isola M; De Martino M; Chiusolo P; Martino M; Galieni P; Rivela P; Bernasconi P; Parma M; Carluccio P; Mangiacavalli S; Mordini N; Benedetti E; Russo D; Stanghellini MTL; Rambaldi A; Giaccone L; Pucillo M; Nozzoli C;

Post Transplant Cyclophosphamide as GvHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: the PHYLOS trial. in Blood advances / Blood Adv. 2025 Feb 10:bloodadvances.2024015173. doi: 10.1182/bloodadvances.2024015173.

2025
AOU Città della Salute di Torino

Raiola A; Bruno B; Risitano AM; Mosna F Dr; Cavattoni IM; Onida F; Saporiti GN; Patriarca F; Battista ML; Pavone V; Mele A MD; Chiusolo P; Sica S; Loteta B; di Grazia C; Carella AM; Salvatore D; Morello E; Leoni A; Giaccone L; Bernasconi P; Terruzzi E; Mordini N; Borghero C; Zallio F; Luppi M; Grassi A; Olivieri A; Piras E; et alii...

Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study. in British journal of haematology / Br J Haematol. 2025 Feb;206(2):644-651. doi: 10.1111/bjh.19961. Epub 2024 Dec 22.

2025
AOU Città della Salute di Torino

Sorà F; Zinzani P; Tisi MC; Arcaini L; Krampera M; Patriarca F; Botto B; Angelillo P; Grillo G; Massaia M; Martino M; Farina M; Barbui AM; Cutini I; Ljevar S; Musso M; De Philippis C; Bonifazi F; Magni M; Chiappella A; Stella F; Bramanti S; Pennisi M; Carniti C; Corradini P;

Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study. in Cancer medicine / Cancer Med. 2024 Nov;13(22):e70266. doi: 10.1002/cam4.70266.

2024
AOU Città della Salute di Torino

Mancuso K; Mina R; Rocchi S; Antonioli E; Petrucci MT; Fazio F; Gozzetti A; Salvini M; Cartia CS; Bertuglia G; Patriarca F; Dalla Palma AB; Barbato S; De Cicco G; Bigi F; Favero E; Tacchetti P; Pantani L; Rizzello I; Puppi M; Talarico M; Solli V; Kanapari A; Cavo M; Zamagni E;

Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. in Leukemia / Leukemia. 2024 May;38(5):1107-1114. doi: 10.1038/s41375-024-02213-x. Epub 2024 Mar 8.

2024
AOU Alessandria
AOU Città della Salute di Torino

Corradini P; Zinzani PL; Miceli R; Guidetti A; Saccardi R; Bermema A; Ferrari S; Martelli M; Ferreri AJM; Pennisi M; Galli E; Patriarca F; Zacchi G; Krampera M; Grillo G; Novo M; Martino M; Farina M; Musso M; Tisi MC; Bramanti S; Bonifazi F; Dodero A; Cutini I; Angelillo P; Barbui AM; Ljevar S; Magni M; Di Rocco A; et alii...

Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial. in Blood cancer journal / Blood Cancer J. 2024 Aug 21;14(1):141. doi: 10.1038/s41408-024-01116-5.

2024
AO Cuneo
AOU Città della Salute di Torino

Iori AP; Bernasconi P; Corradini P; Russo D; Nagler A; Carella AM; Marotta G; Cerretti R; Rivela P; Terruzzi E; Saporiti G; Pane F; Patriarca F; Saccardi R; Musto P; Chiusolo P; Olivieri A; Milone G; Santarone S; Borghero C; Cavattoni IM; Busca A; Micò MC; Pavoni C; Grassi A; Cavallaro G; Castagna L; Mordini N; Oldani E; et alii...

Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study. in Transplantation direct / Transplant Direct. 2023 Feb 22;9(3):e1451. doi: 10.1097/TXD.0000000000001451. eCollection 2023 Mar.

2023
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Proia A; Carluccio P; Borghero C; Pavone V; Skert C; Iori AP; Luppi M; Vacca A; Falcioni S; Onida F; Bassi S; Mazza P; Nozzoli C; Maffini E; Casini M; Chiusolo P; Carella AM; Olivieri A; Terruzzi E; Natale A; De Gobbi M; Bernasconi P; Bramanti S; Grillo G; Giaccone L; Bruno B; Patriarca F; Martino M; Polverelli N; et alii...

Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102016. doi: 10.1016/j.eclinm.2023.102016. eCollection 2023 Jun.

2023
AOU Città della Salute di Torino

Oliva S; Genuardi E; Paris L; D'Agostino M; Rogers J; Rota-Scalabrini D; Jacob AP; Patriarca F; Luppi M; Bertazzoni P; Velluti C; Capra A; Saraci E; Rossi M; Allegra A; Mina R; Gentile M; Kirsch IR; Belotti A; Cavo M; Bruno B; Musto P; Boccadoro M; Zamagni E; Gay F;

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun.

2023
AOU Città della Salute di Torino

Zamagni E; Oliva S; Gay F; Capra A; Rota-Scalabrini D; D'Agostino M; Belotti A; Galli M; Racca M; Zambello R; Gamberi B; Albano D; Bertamini L; Versari A; Grasso M; Sgherza N; Priola C; Fioritoni F; Patriarca F; De Cicco G; Villanova T; Pascarella A; Zucchetta P; Tacchetti P; Fanti S; Mancuso K; Barbato S; Boccadoro M; Musto P; et alii...

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. in Hematological oncology / Hematol Oncol. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1.

2022
AOU Città della Salute di Torino

Zamagni E; Bringhen S; Consoli U; Frigeri F; Pompa A; Tripepi G; Gamberi B; Gagliardi A; Gangemi D; Ballanti S; Martino M; Stocchi R; Cupelli L; Bonalumi A; Sgherza N; Vincelli D; Botta C; Mimmi S; Iaccino E; Vigna E; Mendicino F; Curci P; Uccello G; Criscuolo C; Belotti A; Cerchione C; Cascavilla N; Palumbo G; Pietrantuono G; et alii...

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. in HemaSphere / Hemasphere. 2022 Sep 30;6(10):e786. doi: 10.1097/HS9.0000000000000786. eCollection 2022 Oct.

2022
AOU Città della Salute di Torino

Sonneveld P; Zweegman S; Cavo M; Nasserinejad K; Broijl A; Troia R; Pour L; Croockewit S; Corradini P; Patriarca F; Wu K; Droogendijk J; Bos G; Hajek R; Teresa Petrucci M; Ypma P; Zojer N; Minnema MC; Boccadoro M;

Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. in Transplantation and cellular therapy / Transplant Cell Ther. 2022 May;28(5):258.e1-258.e8. doi: 10.1016/j.jtct.2022.01.026. Epub 2022 Feb 4

2022
AOU Città della Salute di Torino

Gahrton G; García-Cadenas I; Reguera JL; López-Corral L; Nahi H; Granell M; Einsele H; Bruno B; Fanin R; Herrera P; Patriarca F; Reinoso-Segura M; Caballero-Velázquez T; Pérez-Simón JA;

Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. in Bone marrow transplantation / Bone Marrow Transplant. 2022 Jun;57(6):949-958. doi: 10.1038/s41409-022-01626-5. Epub 2022 Apr 12.

2022
AOU Alessandria
AOU Città della Salute di Torino

Oldani E; Vallisa D; Sacchi N; Vacca A; Tringali S; Parma M; Palazzo G; Onida F; Musso M; Grillo G; Casini M; Baronciani D; Nozzoli C; Cupri A; Luppi M; Chiusolo P; Carluccio P; Sorasio R; Santarone S; Proia A; Picardi A; Cilloni D; Carella AM; Di Grazia C; Brunello L; Patriarca F; Iori AP; Grassi A; Busca A; et alii...

GITMO Registry Study on Allogeneic Transplantation in Patients Aged ?60 Years from 2000 to 2017: Improvements and Criticisms. in Transplantation and cellular therapy / Transplant Cell Ther. 2022 Feb;28(2):96.e1-96.e11. doi: 10.1016/j.jtct.2021.11.006. Epub 2021 Nov 21

2022
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Bonifazi F; Mammoliti S; Oldani E; Ciceri F; Russo D; Selleri C; Sacchi N; Borghero C; Proia A; Skert C; Carluccio P; Pavone V; Iori AP; Falcioni S; Luppi M; Mazza P; Bassi S; Onida F; Vacca A; Nozzoli C; Casini M; Carella AM; Terruzzi E; Olivieri A; Chiusolo P; De Gobbi M; Natale A; Bramanti S; Bernasconi P; et alii...

Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. in Bone marrow transplantation / Bone Marrow Transplant. 2022 Dec;57(12):1758-1764. doi: 10.1038/s41409-022-01565-1. Epub 2022 Sep 3.

2022
AOU Città della Salute di Torino

Mavilio D; Blaise D; Bruno B; Bacigalupo A; Furst S; Santoro A; Chabannon C; Chiusolo P; Sica S; Frieri C; Marotta S; Marano L; Sperotto A; Fanin R; Console G; Loteta B; Savino L; Merla E; Brunello L; Giaccone L; Busca A; Risitano A; Martino M; Carella MA; Patriarca F; Harbi S; Evangelista A; Raiola AM; Mariotti J; et alii...

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. in Cancer / Cancer. 2021 Sep 15;127(18):3413-3421. doi: 10.1002/cncr.33647. Epub 2021 Jun 28.

2021
AOU Città della Salute di Torino

Einsele H; Palumbo A; Straka C; Corradini P; Wäsch R; Gentili S; Schub N; Spada S; Pönisch W; Aquino S; Patriarca F; Montefusco V; Salvini M; Engelhardt M; Offidani M; Günther A; Gay F; Boccadoro M; Sonneveld P; Gramatzki M;

Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. in Transplantation and cellular therapy / Transplant Cell Ther. 2021 May;27(5):406.e1-406.e11. doi: 10.1016/j.jtct.2020.11.021. Epub 2021 Feb

2021
AOU Città della Salute di Torino

Gallina AM; Patriarca F; Andreani M; Celeghini I; Carluccio P; Martino M; Olivieri A; Carella AM; Luppi M; Lamparelli T; Milone G; Papalinetti G; La Rocca U; Borghero C; Zallio F; Chiusolo P; Saporiti G; Guidi S; Fagioli F; Farina L; Russo D; Pioltelli P; Benedetti F; Bernasconi P; Arcese W; Vago L; Cerno M; Bruno B; Sessa M; et alii...

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. in Blood / Blood. 2021 Jun 3;137(22):3027-3036. doi: 10.1182/blood.2020009507.

2021
AOU Alessandria
AOU Città della Salute di Torino

Tacchetti P; Corradini P; Caravita di Toritto T; Patriarca F; Pompa A; Monaco F; Cellini C; Rota-Scalabrini D; Antonioli E; Bernardini A; Giuliani N; Galli M; Marasca R; Tosi P; Benevolo G; Capra A; Cascavilla N; Offidani M; Gaidano G; D'Agostino M; Bonello F; Larocca A; Boccadoro M; Bringhen S;

Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2021 Jul 1;27(13):3695-3703. doi: 10.1158/1078-0432.CCR-21-0134. Epub 2021 Apr 29.

2021
AOU Città della Salute di Torino

Hájek R; Spencer A; Nagler A; Gaidano G; Belotti A; Benevolo G; Patriarca F; Mina R; Ruggeri M; Cascavilla N; de Fabritiis P; Mannina D; Liberati AM; Romano A; Capra A; Corradini P; Offidani M; Petrucci MT; Bertamini L; Zaccaria GM; Sonneveld P; Musto P; Boccadoro M; Gay F;

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. in Haematologica / Haematologica. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513.

2021
AOU Città della Salute di Torino

Gentile M; Specchia G; Derudas D; Galli M; Botta C; Rocco S; Conticello C; Califano C; Giuliani N; Mangiacavalli S; Attingenti E; Lombardo A; Brunori M; Rossi E; Antonioli E; Ria R; Zambello R; Di Renzo N; Mele G; Marcacci G; Musto P; Capalbo S; Cascavilla N; Cerchione C; Belotti A; Criscuolo C; Uccello G; Curci P; Vigna E; et alii...

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. in Blood cancer journal / Blood Cancer J. 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5.

2021
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Corradini P; Monaco F; Boccadoro M; Ballanti S; Offidani M; De Paoli L; De Sabbata G; Aquino S; Paris L; Grasso M; Belotti A; Cellini C; Tacchetti P; Zambello R; Musolino C; Cea M; Bonello F; Rota-Scalabrini D; Patriarca F; Capra A; Petrucci MT; Ciccone G; Liberati AM; Pescosta N; Bringhen S; Falcone AP; Mina R;

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. in Blood cancer journal / Blood Cancer J. 2021 Apr 12;11(4):73. doi: 10.1038/s41408-021-00464-w.

2021
ASL Torino 4
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Hájek R; Sonneveld P; Boccadoro M; Musto P; Guglielmelli T; Di Raimondo F; Corradini P; Aitoro G; Benevolo G; Giuliani N; Patriarca F; Bonello F; de Fabritiis P; Innao V; Zambello R; Cascavilla N; Derudas D; Capra A; Petrucci MT; Gaidano G; Offidani M; Liberati AM; Larocca A; D'Agostino M; Bringhen S;

Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation. in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation / Biol Blood Marrow Transplant. 2020 Oct;26(10):e256-e262. doi: 10.1016/j.bbmt.2020.06.032. Epub 2020

2020
AOU Alessandria
AOU Città della Salute di Torino

Ferrario A; Reda G; Zallio F; Vallisa D; Magagnoli M; Onida F; Fanin R; Quaresmini G; Salvetti C; Coscia M; Frustaci AM; Patriarca F; Bruno B; Barretta F; Scarfò L; Farina L; Corradini P; Montillo M; Farina L; Barretta F; Scarfò L; Bruno B; Patriarca F; Frustaci AM; Coscia M; Salvetti C; Quaresmini G; Fanin R; Onida F; et alii...

Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). in Bone marrow transplantation / Bone Marrow Transplant. 2020 Nov;55(11):2077-2086. doi: 10.1038/s41409-020-0902-9. Epub 2020 Apr 24.